Swiss Rockets, MGI US LLC and Complete Genomics Inc. announced today that they entered into a exclusive license agreement ...
Twist Bioscience is advancing synthetic DNA manufacturing with innovation but remains at the lower end of its 52-week range.
Biomarker testing helps identify effective targeted therapies and avoid those that are less likely to work in certain ...
Researchers have uncovered microbial evidence in the remains of Napoleon’s soldiers from the 1812 Russian retreat. Genetic ...
Genomics has administered a double dose of litigation to Illumina, joining with separate partners in a pair of federal lawsuits accusing the sequencing giant of infringing on nine patents related to ...
New plate-based multiplexing unlocks ultra high-sample and cell-throughput single cell analysis to empower a broad range of ...
TEM secures multiple FDA clearances in 2025, boosting its AI-driven diagnostic portfolio across oncology and cardiology.
New plate-based multiplexing unlocks ultra-high-sample and cell-throughput single cell analysis to empower a broad range of studies.
Zacks.com on MSN
TEM vs. EXAS: Which Genomics Player Offers Greater Upside?
Tempus AI's soaring genomics revenues and Exact Sciences' diagnostic breakthroughs spotlight two distinct routes to precision ...
AI and accelerated computing are transforming the bio/pharmaceutical sector by addressing organizational, technological, and ...
The "Prostate Cancer Biomarkers Market Size and Growth Trends and Companies 2025-2033" has been added to ResearchAndMarkets.com's offering. The Prostate Cancer Biomarkers Market is expected to reach ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback